ATE416175T1 - 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen - Google Patents
2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungenInfo
- Publication number
- ATE416175T1 ATE416175T1 AT02712572T AT02712572T ATE416175T1 AT E416175 T1 ATE416175 T1 AT E416175T1 AT 02712572 T AT02712572 T AT 02712572T AT 02712572 T AT02712572 T AT 02712572T AT E416175 T1 ATE416175 T1 AT E416175T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- arylaminopyrimidines
- gsk3
- related diseases
- solution
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229920001661 Chitosan Polymers 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 210000002445 nipple Anatomy 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26990301P | 2001-02-20 | 2001-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE416175T1 true ATE416175T1 (de) | 2008-12-15 |
Family
ID=23029104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02712572T ATE416175T1 (de) | 2001-02-20 | 2002-02-18 | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7078410B2 (de) |
| EP (1) | EP1423388B1 (de) |
| JP (1) | JP4309657B2 (de) |
| KR (1) | KR20030076688A (de) |
| CN (1) | CN100415744C (de) |
| AT (1) | ATE416175T1 (de) |
| BR (1) | BR0207096A (de) |
| CA (1) | CA2435177A1 (de) |
| DE (1) | DE60230160D1 (de) |
| ES (1) | ES2316546T3 (de) |
| IL (1) | IL156784A0 (de) |
| MX (1) | MXPA03007266A (de) |
| NO (1) | NO20033677L (de) |
| NZ (1) | NZ527009A (de) |
| WO (1) | WO2002066480A2 (de) |
| ZA (1) | ZA200306175B (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| HRP20050089B1 (hr) | 2002-07-29 | 2015-06-19 | Rigel Pharmaceuticals | Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti |
| EP1570847B1 (de) * | 2002-12-03 | 2012-04-25 | Kyorin Pharmaceutical Co., Ltd. | Phosphodiesterase 10a-hemmer zur behandlung der parkinson-krankheit, der huntington-krankheit und der schizophrenie |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP4886511B2 (ja) | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| GB0402277D0 (en) * | 2004-02-03 | 2004-03-10 | Astrazeneca Ab | Chemical compounds |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| KR20070084067A (ko) * | 2004-10-13 | 2007-08-24 | 와이어쓰 | Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
| ATE540035T1 (de) | 2004-11-24 | 2012-01-15 | Rigel Pharmaceuticals Inc | Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US20090099160A1 (en) * | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
| CN101115761B (zh) | 2005-01-19 | 2012-07-18 | 里格尔药品股份有限公司 | 2,4-嘧啶二胺化合物的前药及其应用 |
| US20070155738A1 (en) * | 2005-05-20 | 2007-07-05 | Alantos Pharmaceuticals, Inc. | Heterobicyclic metalloprotease inhibitors |
| EA013525B1 (ru) * | 2005-05-20 | 2010-06-30 | Алантос-Фармасьютикалз Холдинг, Инк. | Гетеробициклические ингибиторы металлопротеазы и их применение |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| AU2006254840B2 (en) | 2005-06-08 | 2012-08-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US20080214560A1 (en) * | 2005-10-03 | 2008-09-04 | Astrazeneca Ab | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| GB0520958D0 (en) | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| US8097617B2 (en) * | 2006-03-31 | 2012-01-17 | Novartis Ag | Organic compounds |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| CA2654670A1 (en) * | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| JP5179509B2 (ja) | 2006-12-08 | 2013-04-10 | エフ．ホフマン−ラ ロシュ アーゲー | 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用 |
| MX2009006704A (es) | 2006-12-22 | 2009-06-30 | Astex Therapeutics Ltd | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. |
| MX2009006706A (es) | 2006-12-22 | 2009-07-02 | Astex Therapeutics Ltd | Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos. |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| US8067409B2 (en) | 2007-11-27 | 2011-11-29 | Abbott Laboratories | Protein kinase inhibitors |
| WO2009103032A1 (en) | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| ES2605815T3 (es) | 2008-07-01 | 2017-03-16 | Ptc Therapeutics, Inc. | Moduladores de la expresión de la proteína Bmi-1 |
| CA2728228A1 (en) | 2008-07-14 | 2010-01-21 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| NZ602832A (en) | 2008-07-14 | 2014-04-30 | Gilead Sciences Inc | Fused heterocyclic hdac inhibitor compounds |
| WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| MX2011001090A (es) | 2008-07-28 | 2011-03-15 | Gilead Sciences Inc | Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno. |
| UY32203A (es) * | 2008-10-29 | 2010-05-31 | Astrazeneca Ab | Amino pirimidinas y su uso en terapia |
| CN101735211B (zh) * | 2008-11-04 | 2012-11-14 | 复旦大学 | 2,3-二氢[1,5]苯并噻氮杂*类化合物或其盐在制备GSK-3β抑制剂中的用途 |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| ES2463826T3 (es) | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| WO2010144371A1 (en) | 2009-06-08 | 2010-12-16 | Gilead Colorado, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| JP5641664B2 (ja) | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| CN102391264A (zh) * | 2011-09-21 | 2012-03-28 | 河北九派制药有限公司 | 6-溴咪唑并[1,2-a]吡啶的制备方法 |
| EP2671885A1 (de) | 2012-06-05 | 2013-12-11 | Ares Trading S.A. | Imidazo-Oxadiazol- und Imidazo-Thiadiazolderivate |
| AU2013283426B2 (en) | 2012-06-26 | 2018-02-22 | Janssen Pharmaceutica Nv | Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| WO2014009305A1 (en) | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| DK2900238T3 (en) | 2012-09-28 | 2018-03-12 | Univ Vanderbilt | CONDENSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS |
| EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
| US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| CN106362155A (zh) * | 2016-10-08 | 2017-02-01 | 无锡汉强医药科技有限公司 | Gsk3抑制剂在制备治疗尼曼匹克病c型疾病中的应用 |
| BR112019011211A2 (pt) | 2016-12-16 | 2019-10-15 | Basf Se | compostos de fórmula i, composição, métodos para combater ou controlar pragas invertebradas, para proteger plantas em crescimento de ataque ou infestação por pragas invertebradas, semente, uso de um composto e método para tratar ou proteger um animal |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| KR102249521B1 (ko) | 2018-11-14 | 2021-05-07 | 아이알링크 주식회사 | 스마트폰과 동기화되는 pc 인터페이스 장치 및 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0233461B2 (de) | 1986-01-13 | 2002-05-29 | American Cyanamid Company | 4,5,6-Substituierte 2-Pyrimidinamine |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| WO2002020495A2 (en) | 2000-09-06 | 2002-03-14 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
-
2002
- 2002-02-18 ES ES02712572T patent/ES2316546T3/es not_active Expired - Lifetime
- 2002-02-18 WO PCT/SE2002/000270 patent/WO2002066480A2/en not_active Ceased
- 2002-02-18 DE DE60230160T patent/DE60230160D1/de not_active Expired - Lifetime
- 2002-02-18 BR BR0207096-0A patent/BR0207096A/pt not_active IP Right Cessation
- 2002-02-18 MX MXPA03007266A patent/MXPA03007266A/es active IP Right Grant
- 2002-02-18 NZ NZ527009A patent/NZ527009A/en unknown
- 2002-02-18 KR KR10-2003-7010875A patent/KR20030076688A/ko not_active Withdrawn
- 2002-02-18 EP EP02712572A patent/EP1423388B1/de not_active Expired - Lifetime
- 2002-02-18 IL IL15678402A patent/IL156784A0/xx unknown
- 2002-02-18 US US10/468,605 patent/US7078410B2/en not_active Expired - Fee Related
- 2002-02-18 CN CNB028052528A patent/CN100415744C/zh not_active Expired - Fee Related
- 2002-02-18 JP JP2002565994A patent/JP4309657B2/ja not_active Expired - Fee Related
- 2002-02-18 AT AT02712572T patent/ATE416175T1/de not_active IP Right Cessation
- 2002-02-18 CA CA002435177A patent/CA2435177A1/en not_active Abandoned
-
2003
- 2003-08-08 ZA ZA2003/06175A patent/ZA200306175B/en unknown
- 2003-08-19 NO NO20033677A patent/NO20033677L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002066480A2 (en) | 2002-08-29 |
| IL156784A0 (en) | 2004-02-08 |
| US7078410B2 (en) | 2006-07-18 |
| CA2435177A1 (en) | 2002-08-29 |
| BR0207096A (pt) | 2004-01-20 |
| MXPA03007266A (es) | 2003-12-04 |
| ZA200306175B (en) | 2005-01-26 |
| WO2002066480A3 (en) | 2004-04-01 |
| CN1823064A (zh) | 2006-08-23 |
| NO20033677D0 (no) | 2003-08-19 |
| KR20030076688A (ko) | 2003-09-26 |
| CN100415744C (zh) | 2008-09-03 |
| EP1423388A2 (de) | 2004-06-02 |
| US20040106574A1 (en) | 2004-06-03 |
| JP4309657B2 (ja) | 2009-08-05 |
| DE60230160D1 (de) | 2009-01-15 |
| JP2004522777A (ja) | 2004-07-29 |
| EP1423388B1 (de) | 2008-12-03 |
| HK1094697A1 (zh) | 2007-04-04 |
| NO20033677L (no) | 2003-10-02 |
| NZ527009A (en) | 2006-04-28 |
| ES2316546T3 (es) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60230160D1 (de) | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen | |
| BR0210680A (pt) | Processo para a hidrólise de proteìnas do leite | |
| BR0108734A (pt) | Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas | |
| DE59603187D1 (de) | Verfahren zur herstellung von organisch modifizierten aerogelen, bei dem die gebildeten salze ausgefällt werden | |
| WO2004049819A3 (en) | Method for improving the functional properties of a globular protein, protein thus prepared, use thereof and products containing the protein | |
| ATE268124T1 (de) | Flüssige chitosan-enthaltende zusammensetzungen und verfahren zur herstellung und verwendung | |
| CA2527120A1 (en) | Stable aqueous solution of natamycin fungicide | |
| DE60107252D1 (de) | Antimikrobielle zusammensetzung zur behandlung von rindermastitis | |
| ATE355861T1 (de) | Verfahren zur herstellung von absorbierenden sanitärartikeln mit milchsäure produzierenden bakterien | |
| DE69807818D1 (de) | Mittel zum eintauchen von zitzen | |
| DE60034601D1 (de) | Verfahren zur herstellung von polyphenolischen adhäsionsproteinen | |
| BRPI0416088A (pt) | composição, sistema, e método de tratar condições tais como calcificação vascular | |
| ATE362319T1 (de) | Einwertiges salz verbessert die löslichkeit von milchproteinkonzentrat | |
| FR2866890B1 (fr) | Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant | |
| WO2002067952A8 (en) | Prophylactic teat treatment | |
| DE69811758D1 (de) | Verwendung von Hyaluronsäure zur Herstellung einer wässrigen Lösung verwendbar als intra-artikulare Reinigungslösung | |
| FR2803205B1 (fr) | Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie | |
| SE0101307D0 (sv) | An effervescent solid composition of matter | |
| BRPI0416427A (pt) | suspensão aquosa e método de preparação de suspensão aquosa | |
| DE60322738D1 (de) | Verfahren zur herstellung einer medizinischen lösung zur herstellung eines medikaments für die peritonealdialyse | |
| DE60013583T8 (de) | Verfahren zur herstellung von arzneimitteln eines basischen hydrophoben wirkstoffs | |
| NO20033707D0 (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
| NO20033706L (no) | Fremgangsmåte for fremstilling av D-pantotensyre og/eller salter som tilsetning til dyrefôr | |
| ATE235824T1 (de) | Verfahren zur herstellung von polyvinylpyrrolidon-iod in wässriger lösung | |
| BR0317681A (pt) | Método para tratamento de produtos alimentìcios processados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |